Literature DB >> 11793352

Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.

Elliott J Mufson1, Shuang Y Ma, John Dills, Elizabeth J Cochran, Sue Leurgans, Joanne Wuu, David A Bennett, Syed Jaffar, Michelle L Gilmor, Alan I Levey, Jeffrey H Kordower.   

Abstract

The long-held belief that degeneration of the cholinergic basal forebrain was central to Alzheimer's disease (AD) pathogenesis and occurred early in the disease process has been questioned recently. In this regard, changes in some cholinergic basal forebrain (CBF) markers (e.g. the high affinity trkA receptor) but not others (e.g., cortical choline acetyltransferase [ChAT] activity, the number of ChAT and vesicular acetylcholine transporter-immunoreactive neurons) suggest specific phenotypic changes, but not frank neuronal degeneration, early in the disease process. The present study examined the expression of the low affinity p75 neurotrophin receptor (p75(NTR)), an excellent marker of CBF neurons, in postmortem tissue derived from clinically well-characterized individuals who have been classified as having no cognitive impairment (NCI), mild cognitive impairment (MCI), and mild AD. Relative to NCI individuals, a significant and similar reduction in the number of nucleus basalis p75(NTR)-immunoreactive neurons was seen in individuals with MCI (38%) and mild AD (43%). The number of p75(NTR)-immunoreactive nucleus basalis neurons was significantly correlated with performance on the Mini-Mental State Exam, a Global Cognitive Test score, as well as some individual tests of working memory and attention. These data, together with previous reports, support the concept that phenotypic changes, but not frank neuronal degeneration, occur early in cognitive decline. Although there was no difference in p75(NTR) CBF cell reduction between MCI and AD, it remains to be determined whether these findings lend support to the hypothesis that MCI is a prodromal stage of AD. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793352     DOI: 10.1002/cne.10122

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  64 in total

1.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

Review 2.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

Review 3.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

4.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

Review 5.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 6.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

7.  Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation.

Authors:  Brice Williams; Ann-Charlotte Granholm; Kumar Sambamurti
Journal:  Neurosci Lett       Date:  2006-12-19       Impact factor: 3.046

Review 8.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

10.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

Authors:  Chelsea T Tiernan; Stephen D Ginsberg; Bin He; Sarah M Ward; Angela L Guillozet-Bongaarts; Nicholas M Kanaan; Elliott J Mufson; Scott E Counts
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.